|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 332.00 EUR | -0.75% |
|
+1.84% | -7.13% |
| 21/07 | Virbac: Impressive execution in Q2; we smell a guidance upgrade in Q3 |  |
| 21/07 | Despite the escalation in the Middle East, European stocks stay the course |  |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Sector Veterinary Drugs
| Capi. | Sales Growth | Profitability | Finances | EV / Sales | P/E | |
|---|---|---|---|---|---|---|
 | 316.68Cr | |||||
| 3.16TCr | |||||
| 1.24TCr | |||||
| 362.51Cr | |||||
| 184.16Cr | |||||
| 180.59Cr | - | - |
- Stock Market
- Stocks
- VIRP Stock
- Charts Virbac
- Sector Chart
Select your edition
All financial news and data tailored to specific country editions
